Friday, 06 March 2026
Experts are warning that far from being over diagnosed, people with ADHD are waiting too long for assessment, support and treatment.
In a new study, published in the British Journal of Psychiatry, experts say there is no robust evidence that ADHD is over-diagnosed in the UK.
The study was led by experts from the University of Southampton along with colleagues from the University of Cambridge and the University of Nottingham.
The new paper refutes the view that ‘nowadays everyone has ADHD’ which is gaining traction in public discourse and has been amplified by some leading politicians, as demand rises for NHS assessments and services.
Bringing together academics, clinicians, people with lived experience and carers, the group say this narrative risks misleading the public and policymakers and overshadows a more pressing concern - unmet need.
While the incidence of ADHD diagnosis has increased significantly since 2020 - particularly in women and young adults - NHS administrative data in England shows no evidence of overdiagnosis with the rate of ADHD diagnosis remaining below the expected levels of ADHD in the population. The recent rise in ADHD diagnosis reflects a catch-up after many years of under recognition and under diagnosis. Hence, rather than ‘overdiagnosis’ the real concern should be the unacceptably long waiting times, sometimes over years, that people experience in the NHS for diagnosis, support and treatment.”
Professor Samuele Cortese from the University of Southampton, and lead author of the paper, said: “Rather than focusing on increases or decreases in diagnostic rates, attention should be directed toward the extent to which those with ADHD are being adequately diagnosed and treated.
“While misdiagnosis and inappropriate diagnosis do occur, the available evidence indicates that under diagnosis and under treatment remain the predominant challenges.”
When standardised diagnostic criteria are applied, the prevalence of ADHD internationally is around 5 per cent in children and 3 per cent in adults.
While prevalence has increased over time, NHS administrative data in England remains substantially below these expected levels, suggesting that many people with ADHD are living without a diagnosis and adequate support.
The group acknowledge that misdiagnosis can occur in some cases, particularly where assessments rely heavily on self-reporting or where alternative conditions are not fully considered.
Professor Tamsin Ford, Head of the Department of Psychiatry at the University of Cambridge, a co-author on the paper, said: “While many more people with ADHD are being recognised and treated, we are failing to support many more. Overdiagnosis is not a problem, but misdiagnosis may be as people are driven into the private sector by long waits; and sadly, missed diagnoses remain common.”
The researchers stress that the absence of biological diagnostic markers means that thorough, multidisciplinary clinical assessment is essential. Field trials show that when clinicians are properly trained, an ADHD diagnosis is among the most reliable for a mental health condition.
“Similar to physiological traits, such as blood pressure or weight, ADHD symptoms are distributed along a continuum,” says Professor Hollis. “But as with hypertension or obesity, there are diagnostic severity thresholds that determine health risks and what interventions should be used. Similarly, in ADHD a risk-stratified stepped-care approach may be useful.”
The team highlight significant pressure on UK services, with long waiting times and growing demand, especially among adults who were not diagnosed in childhood.
They point to figures showing that around 27 per cent of children and young people diagnosed with ADHD reported waiting one to two years, while 14 per cent waited two to three years.
Evidence shows that untreated ADHD is associated with serious long-term risks, while effective treatments are available, backed by strong evidence, and generally well tolerated.
“The costs of untreated ADHD are often overlooked,” says Professor Cortese. “They include increased risk of academic failure, suicidal behaviour, substance abuse, criminality, injury and death. The failure to provide treatments which have been shown to reduce these risks represents a major ethical issue that needs to be urgently addressed.”
The authors call for improved funding, workforce training and a more balanced, evidence-based conversation to ensure accurate diagnosis while expanding access to care for those who need it.
The researchers are supported by the National Institute for Health and Care Research (NIHR), UK Research and Innovation (UKRI) and the Office for Life Sciences.
Story credits
More information is available from Professor Chris Hollis in the School of Medicine at chris.holllis@nottingham.ac.uk
Notes to editors:
About the University of Nottingham
Ranked 97 in the world and 17th in the UK by the QS World University Rankings, the University of Nottingham is a founding member of Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.
The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.
The university is a major employer and industry partner - locally and globally - and our graduates are the third most targeted by the UK's top employers, according to The Graduate Market in 2024 report by High Fliers Research. Alongside Nottingham Trent University, we lead the Universities for Nottingham initiative, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home. More news…